We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

RDW Blood Test Can Predict Mortality and Re-Admission Among Elderly, Hospitalized Patients

By LabMedica International staff writers
Posted on 25 May 2022
Print article
Image: Red blood cell distribution width predicts prognoses in elderly, hospitalized patients (Photo courtesy of Pexels)
Image: Red blood cell distribution width predicts prognoses in elderly, hospitalized patients (Photo courtesy of Pexels)

Red cell distribution width (RDW), an index for variation of red blood cell size, has been proposed as a potential marker for poorer outcomes in several aging-related diseases and conditions. The biological mechanisms linking greater variability of RBC size and adverse health-related outcomes are not known, however emerging evidence supports the use of RDW as a marker for biologic aging, disease vulnerability, oxidative stress and chronic inflammation. Now, new research has found that higher RDW is associated with increased rates of in-hospital mortality and hospital re-admission among older (>60) patients.

In a retrospective analysis, investigators at Sutter’s California Pacific Medical Center (CPMC, Davis, CA, USA) studied 94,617 patients aged >60 who were hospitalized between January 2013 to December 2017 at Sutter Health. A total of 167,292 admissions were included. The RDW was measured during hospital admission and categorized with 1% intervals. The primary outcome was the rate of in-hospital mortality; secondary outcomes included 30-day re-admission rate and length of hospital stay.

Results showed the overall in-hospital mortality rate was 6.3%. As the RDW value increased, the rate of in-hospital mortality increased from 2.7% for the lowest RDW category to 12.2% in the highest category (p-trend <0.001). The overall 30-day re-admission rate after discharge was 12.5% and the rate of 30-day readmission also increased with increasing RDW categories (7.4% in the lowest group vs. 15.8% in the highest group, p-trend <0.001). Patients with the highest RDW values at admission stayed 1.5–2.0 times longer in the hospital than patients with lower RDW values who were admitted for the same causes.

“Greater variability of red blood cell size is significantly associated with worse prognosis in hospitalized elderly patients, indicating higher mortality, greater risk of early re-admission and longer hospital stay days. Risk stratification strategies for hospitalized elderly should include RDW value,” said Steve Cummings, M.D., lead author of the study, director of the SFCC and a principal investigator at CPMC.

“Predicting the risk of mortality and re-admission are critical for in-patient care. An accurate risk classification strategy for patients can also improve outcomes in clinical practice,” added Warren Browner, M.D., co-author of the study and CEO of CPMC. “However, there are no strong predictors of mortality or early re-admission that can be applied across multiple aging-related diseases. These findings provide the potential of RDW value, one of the most common laboratory tests that are performed for most hospitalized patients, as a biomarker for poorer prognosis or vulnerability in hospitalized elderly patients.”

Related Links:

Automated ELISA-IFA-BLOT Processor AP 22
Gold Supplier
Pipette Tips
Sapphire Pipette Tips
Gold Supplier
Monkeypox Virus Real Time PCR Kit
Monkeypox Virus Real Time PCR Kit
Microplate Incubator Shaker
iShak TS4 NXT

Print article



view channel
Image: Fujirebio has acquired ADx NeuroSciences for 40 million Euros (Photo courtesy of Pexels)

Fujirebio Acquires ADx NeuroSciences to Speed Development of Neurodegenerative Diseases Diagnostic Tests

Fujirebio Holdings, Inc. (Tokyo, Japan) has announced the acquisition of ADx NeuroSciences (Gent, Belgium) for EUR 40 million in a deal that is expected to close in July 2022, pending the satisfaction... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.